MedTrace Logo

Nt-proBNP Guided Primary Prevention of CV Events in Diabetic Patients

NCT00562952 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 300

Last updated 2012-05-03

No results posted yet for this study

Summary

Increased levels of NT-proBNP are known to increase the risk of cardiac events in diabetic patients. The other way around, patients with normal values have an excellent prognosis on short-term. We intend in our study to proof the hypothesis, whether it is possible to decrease NT-proBNP levels by intensified cardiac prevention care We aim those patients, who already have elevated levels, although no history of a cardiac disease. This decrease in NT-proBNP should be translated consequently in a decrease in cardiac events

Conditions

Interventions

DRUG

Telmisartan, Bisoprolol

Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point

DRUG

placebo

no intervention

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Martin P Huelsmann, MD · Medical University of Vienna Dept.of Cardiology

  • Richard Pacher, MD · Medical University of Vienna Dept. of Cardiology

  • Martin Clodi, MD · Medical University of Vienna Dept. of Endocrinology

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00562952 on ClinicalTrials.gov